A new strategy to reduce antimicrobial resistance and save lives
Aranda helps governments ensure the right antimicrobial is available in the right place at the right time. This means patients get the treatment they need, and health systems can slow the spread of resistance.
Antimicrobial resistance is one of the world’s most urgent health threats. But the global response has focused largely on the development of new antibiotics, while the delivery problem remains unsolved.
In low- and middle-income countries, this delivery failure is not one problem. It is a chain reaction:
- Overuse accelerates resistance
- Resistance makes reserve medicines indispensable
- Reserve medicines remain out of reach because manufacturers have no commercial reason to register them in countries with markets which are too small in size or value
The result is a system where patients die from infections that are treatable elsewhere, governments overspend on volatile procurement and/or buy drugs which no longer work, and innovators struggle to generate sustainable returns from medicines the world urgently needs.
Aranda exists to break that cycle.
We align governments, manufacturers, clinicians, and innovators around a fixed-price subscription model that gets the right drug to the right patient at the right time. All while slowing resistance, increasing affordability for LMIC governments, and creating a viable market for antimicrobial innovation.
Our Edge
Aranda treats antimicrobial access as a coordination problem – not simply a supply problem, financing problem, or R&D problem.
Our approach brings together disciplines that rarely operate as one: government delivery, pharmaceutical access, emerging-market execution, surveillance, stewardship, and commercial risk management.
That integration is what makes Aranda’s services work. We give governments a single accountable system for antimicrobial access, with reliable supply, embedded stewardship, real-time surveillance, and fixed pricing.
- For countries, this means predictable access, lower long-term cost and better health outcomes for their people.
- For manufacturers, it means sustainable revenue in countries they cannot efficiently serve today.
- For patients, it means the right medicine is there when it is needed.
Our Vision
A world where countries can treat antimicrobial access as core health infrastructure – planned, funded, and delivered reliably and sustainably, without perpetual dependence on donors.
Aranda is designed to achieve an ambitious but attainable goal: to slow antimicrobial resistance over time, while saving lives today.
We work country by country, but our logic is global. When governments can access the full portfolio of antimicrobial medicines and diagnostics, use them appropriately, and fund them through a predictable, economically viable structure, incentives within the system change.
Patients with treatable conditions are cured more quickly, reducing antibiotic use; companies are encouraged to invest in antimicrobial drug development; and governments and clinicians no longer need worry about stockouts or the price of drugs, just which one is the best to use.
Our sustainable approach
The Aranda subscription brings together everything a country needs to deliver antimicrobial access in one measurable, accountable, deliverable, fixed-price package which, according to independent actuaries, can return more in budget savings than it costs.
1. Surveillance
Digitized infrastructure that integrates with existing government systems to track disease patterns, resistance trends, stock levels, prescribing behavior, and outcomes.
2. Medicines & Diagnostics
Reliable access to the full portfolio of antimicrobial medicines and diagnostic consumables – generic and on-patent – when prescribed according to each country’s treatment guidelines.
3. Stewardship
Support to the health system for effective implementation through continuous review of treatment guidelines, clinician training, and compliance monitoring, delivered through an Aranda-funded delivery unit embedded within a Ministry of Health
4. Fixed Pricing
A single annual price over multiple years, with Aranda absorbing supply, pricing, and volume risk so governments can plan with confidence.
5. Sovereign financing
Given the scale of Aranda’s service, we can provide support for governments to access sources of sovereign financing such that they can create budget savings sooner with early Aranda adoption.
By expanding the subscription model beyond single reserve drugs to the full antimicrobial and diagnostics portfolio, Aranda creates the scale needed to generate procurement savings, fund surveillance and stewardship, and support country adoption through trade financing
CONNECT WITH US
Aranda is building an economically-viable approach to solving one of global health’s most urgent and intractable problems.